Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study

The authors wish to make the following corrections to their article: Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2021
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232657/
https://www.ncbi.nlm.nih.gov/pubmed/34234832
http://dx.doi.org/10.7573/dic.2021-5-2
_version_ 1783713682873647104
collection PubMed
description The authors wish to make the following corrections to their article: Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs in Context 2021; 10: 2021-11-1. DOI: 10.7573/dic.2020-11-1
format Online
Article
Text
id pubmed-8232657
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioExcel Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-82326572021-07-06 Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study Drugs Context Corrigendum The authors wish to make the following corrections to their article: Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs in Context 2021; 10: 2021-11-1. DOI: 10.7573/dic.2020-11-1 BioExcel Publishing Ltd 2021-03-01 /pmc/articles/PMC8232657/ /pubmed/34234832 http://dx.doi.org/10.7573/dic.2021-5-2 Text en Copyright © 2021 Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. https://creativecommons.org/licenses/by-nc-nd/4.0/Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
spellingShingle Corrigendum
Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
title Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
title_full Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
title_fullStr Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
title_full_unstemmed Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
title_short Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
title_sort corrigendum: the effect of azoximer bromide (polyoxidonium(®)) in patients hospitalized with coronavirus disease (covid-19): an open-label, multicentre, interventional clinical study
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232657/
https://www.ncbi.nlm.nih.gov/pubmed/34234832
http://dx.doi.org/10.7573/dic.2021-5-2

Ejemplares similares